ID: ALA5279260

Max Phase: Preclinical

Molecular Formula: C12H14F2N3O8P

Molecular Weight: 397.23

Representations

Canonical SMILES:  COC(=O)COP1(=O)OC[C@H]2O[C@@H](n3ccc(N)nc3=O)C(F)(F)[C@@H]2O1

Standard InChI:  InChI=1S/C12H14F2N3O8P/c1-21-8(18)5-23-26(20)22-4-6-9(25-26)12(13,14)10(24-6)17-3-2-7(15)16-11(17)19/h2-3,6,9-10H,4-5H2,1H3,(H2,15,16,19)/t6-,9-,10-,26?/m1/s1

Standard InChI Key:  IKACDFYOKIKUFF-PDZGACDVSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 397.23

Molecular Weight (Monoisotopic): 397.0487

AlogP: 0.07

#Rotatable Bonds: 4

Polar Surface Area: 141.20

Molecular Species: NEUTRAL

HBA: 11

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 11

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa:

CX LogP: -0.69

CX LogD: -0.69

Aromatic Rings: 1

Heavy Atoms: 26

QED Weighted: 0.55

Np Likeness Score: 0.51

References

1. Zhang L, Qi K, Xu J, Xing Y, Wang X, Tong L, He Z, Xu W, Li X, Jiang Y..  (2023)  Design, Synthesis, and Anti-Cancer Evaluation of Novel Cyclic Phosphate Prodrug of Gemcitabine.,  66  (6): [PMID:36867101] [10.1021/acs.jmedchem.3c00006]

Source

Source(1):

• Scientific Literature